Steve Soper's Biography

Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas

Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.

As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.

Affinity Selection of Extracellular Vesicles using Plastic-based Microfluidic Devices for the Molecular Sub-typing of Breast Cancer Patients

Wednesday, 14 December 2022 at 12:00

Add to Calendar ▼2022-12-14 12:00:002022-12-14 13:00:00Europe/LondonAffinity Selection of Extracellular Vesicles using Plastic-based Microfluidic Devices for the Molecular Sub-typing of Breast Cancer PatientsExtracellular Vesicles 2022: Technologies Driving Biological Investigations in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com

We have been developing tools for the diagnosis of a variety of diseases. The commonality in these tools is that they consist of microfluidic devices made from plastics via injection molding. Thus, our tools can be mass produced at low-cost to facilitate bench-to-bed side transition and point-of-care testing (PoCT). We have also been generating novel assays focused on using liquid biopsy samples that are enabled using microfluidics. In this presentation I will talk about the evolution of our fabrication efforts of plastic-based microfluidic and nanofluidic devices as well their surface modification to make the devices biocompatible for in vitro diagnostics. One tool that we have generated is a plastic device (38 × 42 mm) that consists of 1.5M pillars, which are surface decorated with affinity agents targeting certain disease-associated extracellular vesicles (EVs). The affinity agents are covalently attached to the surface of the microfluidic device using a hetero-bifunctional linker, which consists of a coumarin moiety to allow for the photolytic release of the captured EVs using a blue-light LED to minimize photodamage to the EVs’ molecular cargo. In this presentation, I will discuss the utility of these microfluidic devices using EVs as a source of mRNAs for molecular sub-typing of breast cancer patients. EVs were affinity selected from breast-cancer patients’ plasma by searching for both epithelial and mesenchymal expressing EVs to allow for highly efficient sub-typing using the PAM50 gene panel.

Add to Calendar ▼2022-12-12 00:00:002022-12-14 00:00:00Europe/LondonExtracellular Vesicles 2022: Technologies Driving Biological InvestigationsExtracellular Vesicles 2022: Technologies Driving Biological Investigations in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors